Estimation of Metformin Hydrochloride and Voglibose in Tablet Dosage Form by RP-HPLC Method by Harikrishnan, S
1 
 
ESTIMATION OF METFORMIN HYDROCHLORIDE AND 
VOGLIBOSE IN TABLET DOSAGE FORM BY RP-HPLC 
METHOD 
A dissertation submitted to 
THE TAMILNADU Dr.M.G.R MEDICAL UNIVERSITY 
CHENNAI- 600 032 
In partial fulfillment of the requirements for the award of degree of 
MASTER OF PHARMACY 
IN 
PHARMACEUTICAL ANALYSIS 
SUBMITTED 
BY 
Reg. No. 261330954 
Under the guidance of 
Prof.Dr.D.Babu Ananth, M.Pharm., Ph.D., 
 
 
 
 
DEPARTMENT OF PHARMACEUTICAL ANALYSIS 
EDAYATHANGUDY.G.S PILLAY COLLEGE OF PHARMACY 
NAGAPATTINAM-611002 
APRIL  2016 
 
2 
 
 
 
Prof.Dr.D.Babu Ananth, M.Pharm., Ph.D.,  
Principal,  
Edayathangudy.G.S. Pillay College of Pharmacy, 
Nagapattinam – 611 002.                                                          
                                                            
                                     CERTIFICATE 
 This is to certify that the dissertation entitled “ESTIMATION OF 
METFORMIN HYDROCHLORIDE AND VOGLIBOSE IN 
TABLET DOSAGE FORM BY RP-HPLC METHOD” submitted by 
M.S.HARIKRISHNAN (Reg No: 261330954) in partial fulfillment for 
the award of degree of Master of Pharmacy to the Tamilnadu Dr. 
M.G.R Medical University, Chennai is an independent bonafide work 
of the candidate carried out under my guidance in, Department of 
Pharmaceutical Analysis, Edayathangudy.G.S Pillay College of 
Pharmacy during the academic year 2015-2016.   
 
Place: Nagapattinam                   Prof.Dr.D.Babu Ananth, M.Pharm., Ph.D., 
Date: 
 
 
 
3 
 
ACKNOWLEDGEMENT 
   I would like to express profound gratitude to Mrs. 
Jothimani.G.S.Pillay, Chairman, E.G.S.Pillay College of Pharmacy, and 
Thiru. S.Paramesvaran, M.Com, FCCA, Secretary, E.G.S.Pillay College of 
Pharmacy. 
I express my sincere and deep sense of gratitude to my guide 
Prof.Dr.D.Babu Ananth, M.Pharm., Ph.D., Principal, E.G.S.Pillay College 
of Pharmacy, for his guidance, invaluable and extreme support, 
encouragement, and co-operation throughout the course of my work. 
I  wish  to  express  my  great  thanks  to Prof.Dr.M.Murugan, 
M.Pharm.,PhD, Director  cum Professor,Head,Department of Pharmaceutics, 
E.G.S.Pillay College of Pharmacy, for his support during my project work. 
I  wish  to  express  my  great  thanks  to Prof.K.Shahul Hameed 
Maraicar, M.Pharm., (PhD), Director  cum Professor , Department     of 
Pharmaceutics, E.G.S.Pillay College of Pharmacy, for his support during my 
project work.  
 I would like to extend my thanks to all the Teaching Staff and Non 
Teaching Staff, who are all, supported me for the successful completion of my 
project work.        
  
 
 
 
 
 
 
4 
 
 
INDEX 
 
S.NO 
 
CONTENTS 
1 INTRODUCTION 
2 LITERATURE REVIEW 
3 AIM & OBJECTIVE 
4 PLAN OF WORK 
5 DRUG PROFILE 
6 MATERIALS & METHODS 
7 RESULTS & DISCUSSION 
8 SUMMARY 
9 CONCLUSION 
10 BIBLIOGRAPHY 
 
 
 
 
 
 
 
5 
 
 
INTRODUCTION 
            Analytical chemistry is a branch of chemistry that Ideals with the 
separation, identification and determination of components in a sample. It is the 
science of making quantitative measurements, which requires background 
knowledge of chemical and physical concepts. Analytical chemistry may be 
defined as the “Science and art of determining the composition of materials in 
terms of the elements or compounds contained”. 
Pharmaceutical analysis plays a major role today, and it can be considered as 
an interdisciplinary subject. Pharmaceutical analysis derives its principles from 
various branches of science like Chemistry, Physics, Microbiology, Nuclear 
Science, Electronics, etc. Analytical method is a specific application of a 
technique to solve an analytical problem. Analytical instrumentation plays an 
important role in the production and evaluation of new products and in the 
protection of consumers and the environment. This instrumentation provides 
the lower detection limits required to assure safe foods, drugs, water and air  
Pharmaceutical analysis techniques are applied mainly in two areas  
 Traditionally, analytical chemistry has been split into two main types, 
qualitative and quantitative: 
1.  Qualitative  
Qualitative analysis  is to establish the presence of a given element or  
compound in a sample.  
2.  Quantitative  
Quantitative analysis  is to establish the amount of a given element or 
compound in a sample.  
Specific Technologies and Instrumentation 
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A) Spectrometric techniques 
o Ultraviolet and visible Spectrophotometry 
o Fluorescence and phosphorescence Spectrophotometry 
o Atomic Spectrometry (emission and absorption) 
o Infrared Spectrophotometry 
o Raman Spectroscopy 
o X-Ray Spectroscopy 
o Radiochemical Techniques including activation analysis 
o Nuclear Magnetic Resonance Spectroscopy 
o Electron Spin Resonance Spectroscopy 
B) Electrochemical Techniques 
o Potentiometry 
o Voltametry 
o Voltametric Techniques 
o Amperometric Techniques 
o Colorimetry 
o Electrogravimetry 
o Conductance Techniques 
C) Chromatographic Techniques 
o Gas Chromatography 
o High performance Liquid Chromatography 
o Thin Layer Chromatography 
D) Miscellaneous Techniques 
o Thermal Analysis 
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o Mass Spectrometry 
o Kinetic Techniques 
E) Hyphenated Techniques 
o GC-MS (Gas Chromatography – Mass Spectrometry) 
o ICP-MS (Inductivity Coupled Plasma Mass Spectrometry) 
o GC-IR (Gas Chromatography – Infrared Spectroscopy) 
o MS-MS (Mass Spectrometry – Mass Spectrometry) 
ANALYTICAL METHOD DEVELOPMENT 
Methods are developed for new products when no official methods are 
available.  Alternate methods for existing (non-Pharmacopoeial) products are 
developed to reduce the cost and time for better precision and ruggedness. Trial 
runs are conducted, method is optimized and validated.  When alternate method 
proposed is intended to replace the existing procedure comparative laboratory 
data including merit / demerits are made available 
Steps of method development: 
Documentation starts at the very beginning of the development process, a 
system for full documentation of the development studies must be established. 
All data relating to these studies must be recorded in laboratory notebook or an 
electronic database. 
1. Analyte standard characterization 
All known information about the analyte and its structure is collected i.e., 
physical and chemical properties. 
The standard analyte (≈100% purity) is obtained.  Necessary arrangement is 
made for the proper storage (refrigerator, desicators, freezer). When multiple 
components are to be analyzed in the sample matrix, the number of 
components is noted, data is assembled and the availability of standards for 
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each one is determined. Only those methods (spectroscopic, MS, GC, HPLC 
etc.,) that are compatible with sample stability are considered. 
 
2. Method requirements 
The goals or requirements of the analytical method that need to be developed 
are considered and the analytical figures of merit are defined.  The required 
detection limits, selectivity, linearity, range, accuracy and precision are 
defined.  
3. Literature search and prior methodology 
The literature for all types of information related to the analyte is surveyed. For 
synthesis, physical and chemical properties, solubility and relevant analytical 
methods.Books, periodicals, chemical manufacturers and regulatory agency 
compendia such as USP / NF, AOAC and ASTM publications are reviewed.  
Chemical Abstracts Service (CAS) automated computerized literature searches 
are convenient. 
4. Choosing a method 
Using the information in the literatures and prints, methodology is adapted.  
The methods are modified wherever necessary.  Sometimes it is necessary to 
acquire additional instrumentation to reproduce, modify, improve or validate 
existing methods for in-house analytes and samples. 
If there are no prior methods for the analyte in the literature, from analogy, the 
compounds that are similar in structure and chemical properties are 
investigated and are worked out. There is usually one compound for which 
analytical method already exist that is similar to the analyte of interest. 
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5. Instrumental setup and initial studies 
The required instrumentation is setup.  Installation, operational and 
performance qualification of instrumentation using laboratory standard 
operating procedures (SOP’s) are verified. 
Always new consumables (e.g. solvents, filters and gases) are used, for 
example, method development is never started, on a HPLC column that has 
been used earlier.  
The analyte standard in a suitable injection / introduction solution and in 
known concentrations and solvents are prepared.  It is important to start with an 
authentic, known standard rather than with a complex sample matrix.  If the 
sample is extremely close to the standard (e.g., bulk drug), then it is possible to 
start work with the actual sample. 
6. Optimization 
During optimization one parameter is changed at a time, and set of conditions 
are isolated, rather than using a trial and error approach.  Work has been done 
from an organized methodical plan, and every step is documented (in a lab 
notebook) in case of dead ends. 
 
7. Documentation of analytical figures of merit 
The originally determined analytical figures of merit limit of quantificatation 
(LOQ), Limit of detection (LOD), linearity, time per analysis, cost, sample 
preparation etc., are documented. 
 
8. Evaluation of method development with actual samples 
The sample solution should lead to unequivocal, absolute identification of the 
analyte peak of interest apart from all other matrix components.  
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9. Determination of percent recovery of actual sample and 
demonstration of quantitative sample analysis 
Percent recovery of spiked, authentic standard analyte into a sample matrix that 
is shown to contain no analyte is determined.  Reproducibility of recovery 
(average +/- standard deviation) from sample to sample and whether recovery 
has been optimized has been shown.  It is not necessary to obtain 100% 
recovery as long as the results are reproducible and known with a high degree 
of certainty. 
The validity of analytical method can be verified only by laboratory studies.  
Therefore documentation of the successful completion of such study is a basic 
requirement for determining whether a method is suitable for its intended 
applications.  
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INTRODUCTION TO VALIDATION 
Validation 
Validation of an analytical method is the process by which it is established, by 
laboratory studies, that the performance characteristics of the method meet the 
requirements for the intended analytical applications 
Validation is defined as follows by different agencies 
Food and Drug administration (FDA) 
Establishing documentation evidence, which provides a high degree of 
assurance that specific process, will consistently produce a product meeting its 
predetermined specification and quality attributes. 
World Health Organization (WHO) 
Action of providing that any procedure, process, equipment, material, activity, 
or system actually leads to the expected results 
European Committee (EC) 
Action of providing in accordance to the principles of good manufacturing 
practice that any procedure, process, equipment, material, activity or system 
actually leads to the expected results. In brief validation is a key process for 
effective Quality Assurance. 
Reasons for Validation 
There are two important reasons for validating assays in the pharmaceutical 
industry. The first, and by for the most important, is that assay validation is an 
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integral part of the quality-control system. The second is that current good 
manufacturing practice regulation requires assay validation. 
 
 
Steps followed for validation procedures 
o Proposed protocols or parameters for validations are established. 
o Experimental studies are conducted. 
o Analytical results are evaluated. 
o Statistical evaluation is carried out. 
o Report is prepared documenting all the results. 
 
Objective and Parameters of Analytical Method Validation 
The purpose of validation of an analytical procedure is to demonstrate that it is 
suitable for its intended purpose.  According to ICH guidelines, typical 
analytical performance characteristics that should be considered in the 
validation of the types of methods are 
1. Accuracy 
2. Precision 
3. Specificity 
4. Detection Limit 
5. Quantification Limit 
6. Linearity 
7. Range 
8. Ruggedness 
9. Robustness 
1. Accuracy 
The accuracy is the closeness of the measured value to the true value for the 
sample. The ICH documents recommended that accuracy should be assessed 
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using a minimum of nine determinations over a minimum of three 
concentrations levels the specified range ( i.e, three concentrations and three 
replicates of each concentration) 
Accuracy was tested (% Recovery and % RSD of individual measurements) by 
analyzing samples at least in triplicate, at each level (80,100 and 120 % of label 
claim) is recommended. For each determination fresh samples were prepared 
and assay value is calculated. Recovery was calculated from regression 
equation obtained in linearity study. Accuracy was determined from the mean 
relative error for a set of replicate analysis (i.e. the difference between 
measured and nominal concentration) for spiked samples. 
 
 
2. Precision 
The precision of an analytical procedure expresses the closeness of agreement 
between the series of measurements obtained from multiple sampling of the 
same homogenous sample under the prescribed conditions. Precision of an 
analytical method is usually expressed as the standard deviation, relative 
standard deviation or coefficient of variations of a series of measurements. The 
ICH documents recommend the repeatability should be assessed using a 
minimum of nine determinations covering specified range of procedure. 
Precision may be the measure of either the degree of reproducibility or 
repeatability of the analytical method under normal operating conditions. 
Repeatability:  
Repeatability expresses the precision under the same operating condition over a 
short interval of time. Repeatability is also termed intra – day assay precision. 
Intermediate Precision: Intermediate precision expresses with in laboratories 
variations: different days, different analyst and different equipment. 
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Reproducibility:  
When the procedure is carried out by different analyst in different laboratories 
using different equipment, regents and laboratories setting. Reproducibility was 
determined by measuring repeatability and the intermediate precision. 
Reproducibility is assayed by means of an inter-laboratory trial. 
3. Specificity 
An investigation of specificity should be conducted during the validation of 
identification tests, the determination of impurities. 
An ICH document defines specificity as the ability to assess unequivocally the 
analyte in the presence compounds that may be expected to products and 
matrix components. 
The definition has the following implications: 
Identification test: Suitable identification tests should be able to discriminate 
compounds of closely related structure which are likely to be present .Ensure 
identity of an analyte .The analyte should have no interference from other 
extraneous components and be well resolved from them. 
Purity Test: To ensure that all the analytical procedures performed allow an 
accurate statement of the content of impurity of the content of impurity of an 
analyte i.e. related substances test, heavy metals, residual solvents etc. 
Assay: To provide an exact result, this allows an accurate statement on the 
content or potency of the analyte in a sample. 
 Detection Limit 
It is the lowest amount of analyte in a sample that can be detected, but not 
necessarily quantities as an exact value, under the stated experimental 
conditions. The detection limit is usually expressed as the concentration of 
analyte (percentage parts per million) in the sample. 
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4.Determination of detection limit 
For instrumental and non- instrumental methods detection limit is generally 
determined by the analysis of samples with known concentration of analyte and 
by establishing the minimum level at which the analyte can be reliably 
detected.  
LOD = 3 * SD / slope of calibration curve 
SD = Standard deviation of intercepts 
4.Quantification Limit (QL) 
It is the lowest amount of analyte in a sample that can be determined with 
acceptable precision and accuracy under the stated experimental conditions. 
Quantification limit is expressed as the concentration of analyte (e.g- % ppm) 
in the sample. 
 
Determination of quantification limit 
For instrumental and non- instrumental methods, the quantitation limit is 
generally determined by the analysis of samples with known concentration of 
analyte and by establishing the minimum level at which the analyte can be 
determined with acceptable accuracy and precision.  
LOQ = 10 * SD / slope of calibration curve 
SD = Standard deviation of intercepts 
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Based on Standard Deviation of the blank 
Measurement of the magnitude of the analytical background response is 
performed by analyzing an appropriate number of blank samples and 
calculating the standard deviation of these responses. 
 
Based on the calibration curve 
 A specific calibration curve should be studied using the samples, containing an 
analyte in the range of QL. The residuals SD of regression line or the S.D of 
intercepts of regression lines may be used as the S.D. The quantitative limit is a 
parameter of quantitative assay for low levels of compounds in sample 
matrices, and is use particularly for the determination of impurities or 
degradation products. 
6. Linearity and Range 
The linearity of an analytical procedure is its ability to obtain test results that 
are directly proportional to concentration of analyte in samples. The range of 
an analytical is the intervals between the upper and lower concentration 
(amounts) of analyte in the sample for which it has been demonstrated which it 
has been demonstrated that the analytical procedure has a suitable level of 
precision accuracy and linearity. 
Determination of linearity and range 
The linearity and range determined by application of the procedure to a series 
of Samples having analyte concentration spanning the claimed range of 
procedure. When the relationship between response and concentration is not 
linear, standardization may be providing by means of a calibration curve. The 
ICH recommends that for the establishment of linearity a minimum of five 
concentrations normally used. 
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7. Ruggedness 
Degree of reproducibility (Ruggedness) of test results obtained by the analysis 
of the same samples under a variety of condition such as different laboratories, 
different analysts, different instruments etc, normally expressed as the lack of 
influence on test results of operational and environmental variable of the 
analytical method.  
Ruggedness is a measurement of reproducibility of test results under the 
variation in condition normally expected from laboratory to laboratory and 
from analyst to analyst. Degree of representative of test results is then 
determined as a function of the assay variable. 
By analysis of aliquots from homogenous lots in different laboratories, by 
different analyst, using operational and environmental conditions that may 
differs but are still with in the specified parameter of the assay variable.  
8. Robustness 
Robustness of an analytical method is measure of its capacity to remain 
unaffected small but deliberate variations in method parameters and provides 
an indication of its reliability during normal usage. 
Testing varying some or all condition: 
-Column temperature 
-PH of buffer in mobile phase 
-Reagents and flow rate 
-Mobile Phase Changes 
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8. System Suitability 
 System suitability tests are based on the concept that the equipment, 
electronics, analytical operations and samples constitute an integral system that 
can be evaluated as a whole.  
According to USP system suitability are an integral part of chromatographic 
methods.  These tests verify that the resolution and reproducibility of the 
system are adequate for the analysis to be performed.  One consequence of the 
evaluation of robustness and ruggedness should be that a series of system 
suitability parameters is established to ensure that the validity of the analytical 
method is maintained whenever used. 
The parameters that are affected by the changes in chromatographic conditions 
are, 
o Capacity factor (k’), 
o Peak asymmetry / tailing factor (As) 
o Column efficiency (N) and Selectivity () 
o Capacity factor (k') 
k' = (t R- t0) / t 0  
The capacity factor is a measure of the degree of retention of an analyte relative 
to an unretained peak, where tR is the retention time for the sample peak and to 
is the retention time for an unretained peak.  
Recommendations 
The peak should be well-resolved from the other peaks and the void volume. 
Generally the value of k' is > 2. 
Tailing factor (T) 
A measure of the symmetry of a peak, given by the following equation where 
W0.05 is the peak width at 5% height and f is the distance from peak front to 
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apex point at 5% height. Ideally, peaks should be Gaussian in shape or totally 
symmetrical. 
T = W0.05 / 2f  
The accuracy of quantitation decreases with increase in peak tailing because of 
the difficulties encountered by the integrator in determining where/when the 
peak ends and hence the calculation of the area under the peak. Integrator 
variables are preset by the analyst for optimum calculation of the area for the 
peak of interest. 
Recommendations 
T of </= 2 
Theoretical plate number / Efficiency (N) 
A measure of peak band spreading determined by various methods, some of 
which are sensitive to peak asymmetry. The most common are shown here, 
with the ones most sensitive to peak shape shown first: 
4-sigma / tangential 
N = 16 (tR / W) 2 = L / H  
Half height 
N = 5.54 (tR  / W) 2 = L / H 
Theoretical plate number is a measure of column efficiency,  
Theoretical plate number is a measure of column efficiency, that is, how many 
peaks can be located per unit run-time of the chromatogram, where tR is the 
retention time for the sample peak and W is the peak width. 
N is moderately constant for each peak on a chromatogram with a fixed set of 
operating conditions. H, or HETP, the Height Equivalent of a Theoretical Plate, 
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measures the column efficiency per unit length (L) of the column. Parameters 
which can affect N or H include 
Peak position, particle size in column, flow-rate of mobile phase, column 
temperature, viscosity of mobile phase, and molecular weight of the analyte  
Recommendations 
The theoretical plate number depends on elution time but in general should be 
> 2000. 
Resolution (Rs)  
Ability of a column to separate chromatographic peaks, Resolution can be 
improved by increasing column length, decreasing particle size, increasing 
temperature, changing the eluent or stationary phase. It can also be expressed in 
terms of the separation of the apex of two peaks divided by the tangential width 
average of the peaks. 
                                                
Rs = ΔtR / W1/2 + W2/2;                
Where ΔtR = t2 – t1 
For reliable quantitation, of well-separated peaks are essential for quantitation. 
Recommendations 
Rs of > 2 between the two peaks of interest and the closest potential interfering 
peak (impurity, excipient, degradation product, internal standard, etc.) are 
desirable. 
 Statistical Analysis 
Statistical procedures and representative calculations 
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The consistency and suitability of the developed method are substantiated 
through the statistical analysis like standard deviation, relative standard 
deviation and theoretical plates per meter. 
 
For Accuracy: Standard deviation =  =
1
)xx( 2i


n
 
Where, x = sample, xi = mean value of samples, n = number of samples 
 Relative Standard Deviation =    /xi × 100        
Molar extinction coefficient (mol-1 cm-1) = A/C × L   
Where, A= Absorbance of drug, C= concentration of drug, L= Path length 
Sandell, s sensitivity (µg/cm2/0.001 absorbance units) = C/A×0.001 
Where, C= concentration of drug, A= Absorbance of drug 
Selection of Internal Standard 
A compound added to a sample in known concentration to facilitate the 
qualitative identification and/or quantitative determination of the sample 
components. Internal standards (IS) - substance used as reference in 
quantitative analysis; the internal standard is first mixed with standard 
solutions; later it is added to the unknown, and the ratio of peak heights (or 
areas) of internal standard and analyte is used for quantitative analysis.  
HPLC method validation 
Everyday many chromatographers face the need to develop a HPLC separation 
whereas individual approaches may exhibit considerable diversity; method 
development often follows the series of steps summarized as: 
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Fig .1 Steps involved in HPLC method validation1 
 
 
 
  
 
  
   
 
 
  
 
  
 
  
 
 
1. Introduction on sample 
Define separation goals 
2.    Need    for    special   HPLC 
Procedure, sample, pretreatment, etc 
3.   Choose detector and 
         Detector settings 
4. Choose LC method; 
Preliminary run; estimate best 
separation conditions 
5. Optimize separation condition 
6. Check for problems or requirements 
             for special procedure 
7c. Qualitative 
method 
7a. Recover 
purified material 
7b.Quantitative 
calibration 
23 
 
 
 
 
 
 
 
AIM AND SCOPE OF THE WORK 
 
1. An RP-HPLC method for the Simultaneous estimation of Metformin 
Hcl and Voglibose tablets was developed and Validated in Micro labs in 
Hosur. 
2. The scope of the study is to Development and validation of 
Metformin HCl and Voglibose (500mg&0.3mg) using parameters like 
system precision and system suitability, specificity, precision, accuracy, 
linearity, robustness. 
3. The method has been validated as per the guidelines given by ICH 
requirements to assure that the method consistently meets the 
predetermined specifications and quality attributes. 
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PLAN OF WORK 
Literature survey 
               Through survey of literature available for Metformin HCl and 
Voglibose, regarding their physical and chemical properties, pharmacology, 
pharmacokinetics and reported analytical methods, forms the basis for the 
development of new RP-HPLC method for simultaneous analysis of these 
drugs were designed. 
Procurement of samples 
              Procurement of the drug specimens draws utmosts priority. Both the 
drugs obtained from Micro Laboratory as gift samples and characterized by 
their melting points. 
Development of sample 
1. Selection of solvent system. 
2. Selection of mobile phase. 
3. Simultaneous method development for assay 
4. Analysis of the commercially available formulations. 
               Analytical validations of developed method according to ICH 
guideline parameters, which are selected for method validation, are as follows. 
1. Specificity 
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2. Selectivity 
3. Precision 
        a. Repeatability 
        b. Intermediate precision 
4. Linearity  
5. Accuracy 
6. Robustness 
7. Stability of analytical solutions 
VALIDATION PARAMETERS 
Prepare the mobile phase and arrange all the parameters as per optimized 
method. 
I. SYSTEM PRECISION SYSTEM SUITABILITY 
I.a. SYSTEM PRECISION 
Preparation of standard solution: 
Solution-A:  Accurately weighed 60mg of Voglibose and transfered to a 100ml 
volumetric flask and made up to the volume with diluent. From this 5ml was 
pipetted in to a 50ml volumetric flask and made up to the volume with diluent. 
Solution-B:  Accurately weighed 500mg of Metformin HCl was taken in to a 
500ml volumetric flask and add 300ml of diluent dissolvedd to sonicate for 
5min. Add 5ml of Solution-A and make up with diluent. 
                       Filter the solution through 0.45µ membrane filter. Inject six 
replicated injections in to the HPLC system and calculate the RSD from six 
replicate injections. 
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I.b.SYSTEM SUITABILITY 
1.Blank solution: Purified Water is used as diluent.  
2.Standard preparation:   
Solution-A:   Accurately weighed 60mg of Voglibose and transfed to a 100ml 
volumetric flask and made up to the volume with diluent. From this 5ml was 
pipette out in to a 50ml volumetric flask and made up to the volume with same 
diluent. 
Solution-B:  Accurately weighed 500mg of Metformin HCl was taken in to a 
500ml volumetric flask and add 300ml of diluent dissolvedd to sonicate for 
5min. And add 5ml of Solution-A and make up with diluents. 
 
3.Preparation of test solution: About 0.7200gm of sample was added in to a 
500ml of volumetric flask and added  300ml of diluent and sonicate for 30min 
to obtain uniform dispersion and then volume was made up to the mark with 
diluent. Filtered through 0.45µm membrane filter paper. 
The results are tabulated. 
II. SPECIFICITY 
1. Blank solution:  Purified Water is used as diluents. 
2. Placebo preparation:  
             Weigh accurately 0.720gms placebo powder and transfered to 500 ml 
volumetricflask then added 300ml diluent. Shake and disperse the placebo and 
sonicate for 30 minutes to dissolved the content and make up the volume with 
diluent.  Filter the solution through 0.45µ membrane filter.  Collect the filtrate 
after discarding first few ml of the filtrate.  
3. Standard preparation:   
Solution-A:   Accurately 60mg of Voglibose was weighed and transfer in to a 
100ml volumetric flask and made up to the volume with diluent. From this 5ml 
was pipetted out in to a 50ml volumetric flask and made up to the volume with 
same diluent. 
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Solution-B:  Accurately weighed 500mg of Metformin HCl was taken in to a 
500ml volumetric flask and add 300ml of diluent dissolved to sonicate for 
5min. And add 5ml of Solution-A  and make up with diluent. 
4.Preparation of test solution: about 0.7200gm of sample was added in to a 
500ml of volumetric flask and add  300ml of diluent and sonicate for 30min to 
obtain uniform dispersion and then volume was made up to the mark with 
diluent. Filtered through 0.45µ membrane filter paper.  
III. PRECISION: 
a) Repeatability: establish the repeatability of the analytical method by 
estimating the assay for six sample preparations of the same batch under 
normal operating conditions. Calculate the assay for all six-sample preparations 
and report the %RSD for the same. 
1. Blank solution: Purified water used as diluents 
2. Standard preparation:   
Solution-A:   Accurately weighed 60mg of Voglibose transfered  to a 100ml 
volumetric flask and made up to the volume with diluent. From this 5ml was 
pipette out in to a 50ml volumetric flask and made up to the volume with same 
diluent. 
Solution-B:  Accurately weighed quantity of 500mg of Metformin HCl was 
taken in to a 500ml volumetric flask and adds 300ml of diluent dissolved to 
sonicate for 5min. And add 5ml of Solution-A and make up with diluent. 
3.Preparation of test solution: about 0.7200gm of sample was added in to a 
500ml of volumetric flask and add  300ml of diluent and sonicate for 30min to 
obtain uniform dispersion and then volume was made up to the mark with 
diluents. Filtered through 0.45µ membrane filter paper.  
 
b)Intermediate precision (ruggedness):  intermediate precision study was 
carried out by repeating the complete experiment with different analysts, on 
different days in same laboratory as per the following preparation. 
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1.Blank solution: Purified water used as diluent 
2. Standard preparation:   
Solution-A:   Accurately weighed 60mg of Voglibose  transferred   to a 100ml 
volumetric flask and made up to the volume with diluent. From this 5ml was 
pipette out in to a 50ml volumetric flask and made up to the volume with same 
diluent. 
Solution-B:  Accurately weighed quantities 500mg of Metformin HCl was 
taken in to a 500ml volumetric flask and add 300ml of diluent dissolved to 
sonicate for 5min. And add 5ml of Solution-A and make up with diluent. 
3.Preparation of test solution: about 0.7200gm of sample was added in to a 
500ml of volumetric flask and add  300ml of diluent and sonicate for 30min to 
obtain uniform dispersion and then volume was made up to the mark with 
diluent. Filtered through 0.45µ membrane filter paper.  
IV. LINEARITY: 
Preparation of standard stock solution:   
     Accurately weighed 60mg of Voglibose working standard transferred  to 
100ml volumetric flask and dissolved with diluent and make up the volume 
(solution A).  Accurate weigh 5000mg of Metformin Hcl working standard and 
transfered to 500ml volumetric flask and dissolved it in 300ml of diluent.  Take 
5ml of above solution A and transfered into a 500ml of Metformin Hcl 
volumetric flask and make up the volume with diluent. 
Preparation of linearity solution (50%): Pipette out 5ml from stock solution 
in to a clean 100ml volumetric flask and make up to volume with diluent. 
Preparation of linearity solution (75%): Pipette out 7.5ml from stock 
solution in to a clean 100ml volumetric flask and make up to volume with 
diluent. 
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Preparation of linearity solution (100%): Pipette out 10ml from stock 
solution in to a clean 100ml volumetric flask and make up to volume with 
diluent. 
Preparation of linearity solution (125): Pipette out 12.5ml from stock 
solution in to a clean 100ml volumetric flask and make up to volume with 
diluent. 
Preparation of linearity solution (150%): Pipette out 15ml from stock 
solution in to a clean 100ml volumetric flask and make up to volume with 
diluent. 
Run the solutions as described above. 
V. ACCURACY/ RECOVERY: 
Preparation of standard stock solution-A: 
     Accurately weighed 60mg of Voglibose working standard and transfered in 
to a 100ml volumetric flask and dissolved with diluent and make up the volume 
with diluent (solution A). 
Preparation of linearity solution (50%): Accurately weighed  50mg of 
Metformin HCl in to a 100ml volumetric flask containing about 145mg of 
placebo and 5ml of Solution-A and added 70ml of diluent and sonicate about 
30min to dissolved the content and make up the volume with diluent. Filter the 
solution through 0.45µ membrane filter. Repeat this procedure for another two 
sample preparations. 
 
Preparation of linearity solution (75%): Accurately weighed  75mg of 
Metformin HCl in to a 100ml volumetric flask containing about 145mg of 
placebo and 7.5ml of Solution-A and added 70ml of diluent and sonicate about 
30min to dissolved the content and make up the volume with diluent. Filter the 
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solution through 0.45µ membrane filter. Repeat this procedure for another two 
sample preparations. 
 
Preparation of linearity solution (100%): Accurately weighed  100mg of 
Metformin HCl in to a 100ml volumetric flask containing about 145mg of 
placebo and 10ml of Solution-A and add 70ml of diluent and sonicate about 
30min to dissolved the content and make up the volume with diluent. Filter the 
solution through 0.45µ membrane filter. Repeat this procedure for another two 
sample preparations. 
 
Preparation of linearity solution (125%):Accurately weighed  about 125mg 
of Metformin HCl in to a 100ml volumetric flask containing about 145mg of 
placebo and 12.5ml of Solution-A and add 70ml of diluent and sonicate about 
30min to dissolved the content and make up the volume with diluent. Filter the 
solution through 0.45µ membrane filter. Repeat this procedure for another two 
sample preparations. 
 
Preparation of linearity solution (150%): Accurately weighed  quantity 
about 150mg of Metformin HCl in to a 100ml volumetric flask containing 
about 145mg of placebo and 15ml of Solution-A and add 70ml of diluent and 
sonicate about 30min to dissolved the content and make up the volume with 
diluent. Filter the solution through 0.45µ membrane filter. Repeat this 
procedure for another two sample preparations. 
VI. STABILITY OF ANALYTICAL SOLUTIONS: 
              To establish the stability of analytical solutions by injecting the 
standard and sample solutions at periodic intervals up to 24hours. 
1. Blank solution:Purified water  used as diluents. 
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2. Standard preparation:   
Solution-A:   Accurately weighed 60mg of Voglibose  transfered in to a 100ml 
volumetric flask and made up to the volume with diluent. From this 5ml was 
pipette out in to a 50ml volumetric flask and made up to the volume with same 
diluent. 
Solution-B:  Accurately weighed quantity 500mg of Metformin HCl was taken 
in to a 500ml volumetric flask and add 300ml of diluent dissolved to sonicate 
for 5min. And add 5ml of Solution-A  and make up with diluent. 
3. Preparation of test solution: about 0.7200gm of sample was added in to a 
500ml of volumetric flask and add  300ml of diluent and sonicate for 30min to 
obtain uniform dispersion and then volume was made up to the mark with 
diluent. Filtered through 0.45µ membrane filter paper. 
VII. ROBUSTNESS: 
              To determine the robustness of the analytical method. The robustness 
of an analytical procedure is a measure of its capacity to remain unaffected by 
small but deliberate variations in procedural parameters listed in the procedure 
documentation and provides an indication of its suitability during normal 
usage. Perform the study by evaluating the system suitability parameter and 
estimating the assay under deliberately modified chromatographic conditions. 
Deliberately modified chromatographic conditions: Deliberately modify the 
actual chromatographic conditions specified under the method like flow rate, 
mobile phase composition, column temperature on lower and higher side of the 
actual value. Evaluate system suitability and determine the assay of Metformin 
HCl and Voglibose under these  
 
1. Blank solution: Purified water used as diluent 
2. Standard preparation:   
Solution-A:   Accurately weighed 60mg of Voglibose  transfered in to a 100ml 
volumetric flask and made up to the volume with diluent. From this 5ml was 
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pipette out in to a 50ml volumetric flask and made up to the volume with same 
diluent. 
Solution-B:  Accurately weighed quantitiy 500mg of Metformin HCl was 
taken in to a 500ml volumetric flask and add 300ml of diluent dissolved to 
sonicate for 5min. And add 5ml of Solution-A and make up with diluent. 
3. Preparation of test solution: about 0.7200gm of sample was added in to a 
500ml of volumetric flask and add  300ml of diluent and sonicate for 30min to 
obtain uniform dispersion and then volume was made up to the mark with 
diluent. Filtered through 0.45µ membrane filter paper. Robustness parameters 
S.No Chromatographic parameter Low High 
1 Flow Rate(1.0ml/min) 0.8ml 1.2ml 
2 Column Temperature(25oC) 23oC 27oC 
3 
Mobile phase composition(Buffer: 
Acetonitrile  380:620) 400:600 360:640 
4 Buffer pH(6.5) 6.3 6.7 
 
Separately inject 20µl of blank, standard and sample preparations in to the 
chromatograph set under deliberately modified chromatographic conditions are 
record the chromatograms. Measure the peak responses. 
 
CHROMATOGRAMS 
II. SPECIFICITY: 
Fig- Blank 
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Fig- Placebo 
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Fig- Blank 
 
 
 
 
 
 
 
Fig- Metformin HCl 
 
 
Fig- Voglibose 
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III.PRECISION: 
a) Repeatability: 
Fig- Metformin HCl 
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Fig- Voglibose 
 
b) Intermediate Precision (Day to Day): 
 
Fig- Metformin HCl: 
 
 
Fig- Voglibose 
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LINEARITY: 
Metformin HCl: 
Fig- Metformin HCl 50% 
. 
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Fig- Metformin HCl 75% 
. 
 
 
 
Fig- Metformin HCl 100% 
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Fig- Metformin HCl 125% 
 
 
 
Fig- Metformin HCl 150% 
 
 
 
Voglibose: 
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Fig- Voglibose 50% 
. 
 
 
 
 
Fig- Voglibose 75% 
. 
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Fig- Voglibose 100% 
 
 
 
 
Fig- Voglibose 125% 
 
. 
 
 
Fig- Voglibose 150% 
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ACCURACY/RECOVERY: 
 
Fig-: Metformin HCl 50% 
 
 
Fig-: Voglibose 50% 
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Fig- Metformin HCl 75% 
 
 
 
Fig-: Voglibose 75% 
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. 
 
 
 
 
Fig-: Metformin HCl 100% 
 
 
 
 
Fig-: Voglibose 100% 
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Fig-: Metformin HCl 125% 
 
 
 
Fig- Voglibose 125% 
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Fig-: Metformin HCl 150% 
 
 
 
Fig-: Voglibose 150% 
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STABILITY OF ANALYTICAL SOLUTIONS: 
 
Fig- Blank 
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Fig-: 0th hour- Metformin HCl 
 
 
 
 
Fig-: Voglibose 
 
Fig- 2nd hour- Metformin HCl 
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Fig-: Voglibose 
 
 
 
 
Fig- 4th hour-Metformin HCl 
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Fig-: Voglibose 
 
 
 
 
 
 
51 
 
Fig-: 8th hour- Metformin HCl 
 
 
 
Fig- : Voglibose 
 
 
 
Fig-: 12th hour- Metformin HCl 
52 
 
Fig-: Voglibose 
 
 
 
Fig-: 18th hour- Metformin HCl 
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Fig-: Voglibose 
 
 
 
 
54 
 
 
 
Fig- 24th hour-Metformin HCl 
 
Fig-: Voglibose 
 
ROBUSTNESS: 
Robustness of High flow (1.2ml): 
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Fig-: Metformin HCl 
 
Fig-: Voglibose 
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Robustness of Low flow (0.8ml): 
Fig-: Metformin HCl 
 
 
Fig-: Voglibose 
 
 
 
Robustness of High Temp (27 C): 
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Fig-: Metformin HCl 
 
.  
Fig-: Voglibose 
 
 
 
 
Robustness of Low Temp (23 C): 
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Fig-: Metformin HCl 
 
 
Fig-: Voglibose 
. 
 
 
 
 
Robustness of Mobile phase Changes (Buffer:ACN 400:600): 
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Fig-: Metformin HCl 
 
 
Fig-: Voglibose 
 
 
 
 
Robustness of Mobile phase Changes (Buffer:ACN 360:640): 
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Fig-: Metformin HCl 
 
 
Fig-: Voglibose 
 
. 
 
 
Robustness of High pH (6.7): 
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Fig-: Metformin HCl 
 
. 
 
Fig-: Voglibose 
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Robustness of Low pH (6.3): 
Fig-: Metformin HCl 
 
 
Fig-: Voglibose 
 
                                             RESULTS AND DISCUSSION 
Table:I a.  System suitability parameters for Metformin HCl 
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System 
suitability 
parameter 
Retention 
Time AUC 
Theoretical 
Plates 
Tailing 
factor 
Solution-1 4.27 13441854 5978 1.17 
Solution-2 4.25 13569231 5895 1.15 
Solution-3 4.50 13442183 5965 1.16 
Solution-4 4.31 13395011 5988 1.18 
Solution-5 4.55 13454363 5875 1.05 
Solution-6 4.51 13460528 5896 1.06 
Mean  13460528.33   
S.D  58020.83   
R.S.D  0.431   
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Table:I b. System suitability parameters for Voglibose 
System 
suitability 
parameter Retention Time AUC 
Theoretical 
Plates 
Tailing 
factor 
Solution-1 15.20 119290 5978 1.17 
Solution-2 15.10 120153 5895 1.15 
Solution-3 15.10 119909 5965 1.16 
Solution-4 15.00 120661 5988 1.18 
Solution-5 15.12 120353 5875 1.05 
Solution-6 15.02 120095 5896 1.06 
Mean  120076.8   
S.D  462.8   
R.S.D  0.39   
Acceptance criteria: theoretical plate ≥ 2000, Tailing factor ≤ 2. 
 
Result: 
           Standard solution of Metformin HCl and Voglibose was determined 
under proposed condition chromatogram indicating satisfactory % RSD of peak 
responces,Theoretical plates, tailing factor. 
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II. SPECIFICITY 
          As per optimized method Standard and  Sample preparations are 
prepared and injected. 
Acceptance criteria: No interference at the Rt of Metformin HCl and 
voglibose 
Result: 
          No peak observed due to blank, placebo at the retention time of 
Metformin HCl and Voglibose peak. 
III. PRECISION: 
Table No :III.a Repeatability   
     
  Metformin HCl Voglibose 
Inj AUC Percentage AUC Percentage 
1 13431738 99.7 120983 100.3 
2 13422222 99.8 120974 100.4 
3 13370026 99.3 120641 100.3 
4 13418095 99.7 122999 102.4 
5 13434540 99.8 122562 102.0 
6 13430087 99.6 122700 102.0 
Mean   99.65   101.23 
S.D   0.19   1.00 
R.S.D   0.19   0.99 
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Acceptance Criteria: %RSD of the assay percents should not be more than 2. 
And assay %   percent should be 95-105%. 
Result: 
             The relative Standard deviation for the assay of six sample preparations 
of Metformin HCl and Voglibose was found 0.19% and 0.99%. 
CALCULATION: 
Amount of Metformin HCl present in mg: 
   A x Ws x 500 x P x Aw x1000 
   B x 500x Wt taken x 100 
A = peak area of Metformin HCl for sample preparation 
B = peak area of Metformin HCl for standard preparation      
Ws = weight of Metformin HCl in mg 
P = potency of Metformin HCl 
Aw = average weight of the tablets 
Amount of Metformin HCl in mg: 
=   13431738 x 500 x 500 x 100x 0.7620 x 1000 
    13460528 x 500x 0.7625x100 
= 498.93mg 
Assay in %    =        498.93 x 100               
                                  500 
                       = 99.7 % 
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Amount of Voglibose present in mg: 
   A x Ws x 5x 5 x 500 x P x Aw x1000 
   B x 100x50x 500 x Wt taken x 100 
Assay in % =     Assay in mg x 100 
                                  Label Claim 
Amount of Voglibose in mg: 
    120983 x 60 x 5 x 5 x 500 x 99.62 x 0.7620x 1000 
     120073 x100 x 50 x 500 x 0.7625 x 100 
= 0.3002mg 
 
Assay in %    =        0.3002 x 100               
                                        0.3 
                       = 100.3% 
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IIIb. Intermediate precision:  
Table No:III.b    Intermediate Precision  
  Metformin HCl Voglibose 
Inj AUC Percentage AUC Percentage 
1 13486738 99.5 121125 100.59 
2 13555222 100 120065 100.58 
3 13480030 99.5 121104 100.66 
4 13489595 99.7 123303 102.8 
5 13514540 99.8 119562 101.5 
6 13575591 100.1 123254 102.3 
Mean   99.77   101.41 
S.D   0.25   0.96 
R.S.D   0.25   0.95 
 
Acceptance criteria: %RSD of the assay percents should not be more than 2. 
And assay %   percent should be 95-105%. 
Result: 
          The difference in the assay of relative standard deviation between two 
analysts was found to be within the limits only. 
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CALCULATION: 
Amount of Metformin HCl present in mg: 
  =          A x Ws x 500 x P x Aw x1000 
      B x 500x Wt taken x 100 
 
Amount of Metformin HCl in mg: 
=     13486738 x 500 x  500 x 1000.7620 X 1000 
            13460528 x 500 x 0.7625 x 100 
=    497.93mg 
Assay in %      =        497.93 x 100               
                                        500 
                       = 99.5% 
Amount of Voglibose present in mg: 
   A x Ws x 5x 5 x 500 x P x Aw x1000 
   B x 100x50x 500 x Wt taken x 100 
Assay of Voglibosein mg: 
 =   121125 x 60 x 5 x 5 x 500 x 99.62 x 0.7620X 1000 
     120073 x 100 x 50 x 500 x 0.7625 x 100 
 = 0.3002mg 
Assay in %     =        0.3002 x 100               
                                        0.3 
                      = 100.3% 
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IV. LINEARITY: 
Table No: IVa.  Linearity for Metformin HCl 
 
S.No 
Test con 
in% 
Con in 
PPM 
Replication 
inj Area 
Average 
Area 
1 50% 500.00 
1 6825366 
6807014 2 6795821 
3 6799856 
2 75% 750.00 
1 10052869 
10169429 2 10256892 
3 10198527 
3 100% 1000.00 
1 13592568 
13532506 2 13499256 
3 13505695 
4 125% 1250.00 
1 16892546 
16941649 2 17012036 
3 16920365 
5 150% 1500.00 
1 20165036 
20540572 2 20935242 
3 20521439 
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Acceptance criteria: r2 should not be less than 0.99 
Result: 
        The relationship between the concentration and the peak response of 
Metformin HCl was linear in the specific range and the regression coefficient 
was found to be 0.999. 
Fig No: 1 Linearity curve for Metformin HCl 
 
 
Calculation for ppm: 
Std wt x Pipetted out x 1000 
500      x     100 
 5000 x 5 x 1000            =500 ppm 
 500   x   100 
 5000 x 7.5 x 1000         =750 ppm 
   500   x      100 
5000 x 10 x 1000        =750 ppm 
6807014 
10169429 
13532506 
16941649 
20540572 
y = 3E+06x + 3E+06 
R² = 0.9998 
0
5000000
10000000
15000000
20000000
25000000
500 750 1000 1250 1500
Linearity of Metformin HCl 
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   500   x     100 
 5000 x 12.5 x 1000        =750 ppm 
   500 x      100 
  5000 x 15 x 1000          =750 ppm 
   500   x     100 
Table No: IVb.  Linearity for Voglibose 
 
S.No 
Test con 
in% 
Con in 
PPM 
Replication 
inj Area 
Average 
Area 
1 50% 0.30 
1 61259 
61080 2 60958 
3 61024 
2 75% 0.45 
1 91256 
91691 2 92563 
3 91254 
3 100% 0.60 
1 121356 
121055 2 120598 
3 121210 
4 125% 0.75 
1 150569 
151419 2 151236 
3 152453 
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5 150% 0.90 
1 186025 
187925 2 187536 
3 190215 
 
 
Fig No: 2 Linearity curve For Voglibose 
 
Acceptance criteria: r2 should not be less than 0.99. 
Result: 
        The relationship between the concentration and the peak response of 
Voglibose was linear in the specific range and the regression coefficient was 
found to be 0.998. 
Calculation for PPM: 
Std wt x 5 x 5 x 1000 
100  x 500 x 100 
 60 x 5 x 5 x 1000               =0.30ppm 
61080 
91691 
121055 
151753 
187592 y = 31309x + 28708 
R² = 0.9986 
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
0.30 0.45 0.60 0.75 0.90
Linearity of voglibose 
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  100 x 500 x  100 
60 x 5 x 7.5 x 1000            =0.45ppm 
100  x 500 x 100 
 60 x 5 x 10 x 1000          =0.60ppm 
  100  x 500 x 100 
  60 x 5 x 12.5 x 1000         =0.75ppm 
   100 x 500 x 100 
  60 x 5 x 15 x 1000            =0.90ppm 
   100 x 500 x 100 
 
 
Result: 
 
S.NO Parameter 
Metformin 
HCl Voglibose 
1 Slope 3E 31309 
2 
Correlation-
coefficient 0.999 0.998 
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V. ACCURACY: 
Table No: Va. Recovery data for 50%: 
  Metformin HCl Voglibose 
S.NO 
Con in 
% 
Amount of 
Placebo added 
in (mg) AUC Percentage AUC Percentage 
1 50% 145 6807014 100.6 61080 102.2 
2 50% 145 6799013 100.5 61349 102.7 
3 50% 145 6805555 100.6 60945 102.0 
 
CALCULATION 
Recovery for Metformin HCl in mg:                                                                                                      
Sample area x 500 x 500  
Std area x 500 x 1 
Recovery in % : 
Recovery in mg x 100 
Wt of Std added 
6807014 x 500 x 500             = 2513mg 
13550668 x 500 x 1 
2513                                     =50.25% 
50 
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Recovery for Voglibose: 
Sample area x 60 x 5 x 500  
Std area x 100 x 50 x 1 
Recovery in % : 
Recovery in mg x 100 
Wt of Std added 
61080 x 60 x 5 x 500             = 1514mg 
120983 x 100 x 50 x 1 
 
Table No: Vb. Recovery data for 75%: 
  Metformin HCl Voglibose 
S.NO 
Con in 
% 
Amount of 
Placebo added 
in (mg) AUC Percentage AUC Percentage 
1 75% 145 10120057 99.7 91691 102.3 
2 75% 145 10169429 100.2 91221 101.8 
3 75% 145 10233095 100.8 90976 101.5 
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Table No:Vc.  Recovery data for 100%: 
 
  Metformin HCl Voglibose 
S.NO 
Con in 
% 
Amount of 
Placebo added 
in (mg) AUC Percentage AUC Percentage 
1 100% 145 13411089 99.1 121055 101.3 
2 100% 145 13449139 99.4 122890 102.9 
3 100% 145 13532506 100.0 121495 101.7 
 
 
Table No:Vd.  Recovery data for 125%: 
 
  Metformin HCl Voglibose 
S.NO 
Con in 
% 
Amount of 
Placebo added 
in (mg) 
AUC Percentage AUC Percentage 
1 125% 145 16878822 99.8 151419 101.4 
2 125% 145 16941649 100.2 151315 101.3 
3 125% 145 16836091 99.5 152894 102.4 
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Table No:Ve.  Recovery data for150%: 
 
  Metformin HCl Voglibose 
S.NO Con in 
% 
Amount of 
Placebo added 
in (mg) 
AUC Percentage AUC Percentage 
1 150% 145 20540572 101.2 186259 103.9 
2 150% 145 20739237 102.2 182972 102.1 
3 150% 145 20280016 99.9 183696 102.5 
 
 
Fig No: 3 Recovery curve for Metformin HCl: 
.  
 
 
6803861 
10174194 
13464245 
16885521 
20519942 
y = 3E+06x + 3E+06 
R² = 0.9997 
0
5000000
10000000
15000000
20000000
25000000
50 75 100 125 150
Recovery of Metformin HCl 
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Fig No: 4 Recovery curve for Voglibose 
 
Acceptance criteria: the % recovery of each level should be with in the range 
of 95-105% 
Result: 
       The percentage of recovery of Metformin HCl and Voglibose was found 
97.0% to 103.0%. 
VI. SOLUTION STABILITY OF ANALYTICAL SOLUTIONS 
Table No:VI.  Stability of Analytical solutions 
Time 
interval 
Peak response for 
Metformin HCl 
Peak response for 
Voglibose 
0th hour 13399963 121125 
2th hour 13427856 121883 
4th hour 13409897 120452 
8th hour 13419360 122453 
12th hour 13416331 121563 
61125 
91296 
121813 
151876 
184309 y = 30695x + 29999 
R² = 0.9998 
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
50 75 100 125 150
Recovery of Voglibose 
80 
 
18th hour 13421622 122325 
24th hour 13254286 121350 
Mean 13392759.29 121593 
S.D 61709.67638 700.0449986 
R.S.D 0.46076895 0.575728042 
 
Acceptance criteria: %RSD of the  peak response should not be more than 2. 
Result: 
             %RSD of Metformin HCl and Voglibose was found 0.46 and 0.57 
respectively until  24 hrs. 
 
VII. ROBUSTNESS 
Table No: VII a. Robustness High 
flow(1.2ml):   
 Metformin HCl Voglibose 
S.NO AUC Assay in % AUC Assay in % 
1 13540526 101.7 119025 99.8 
2 13302485 99.5 122546 102.3 
3 13454865 100.5 120458 100.4 
Mean   100.57   100.83 
S.D   1.10   1.31 
R.S.D   1.10   1.29 
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Table No: VII b. Robustness Low 
flow(0.8ml):   
  Metformin HCl Voglibose 
S.NO AUC Assay in % AUC Assay in % 
1 13530522 100.3 122025 100.9 
2 13402452 99.7 123006 102.1 
3 13334865 99.4 122258 101.7 
Mean   99.80   101.57 
S.D   0.46   0.61 
R.S.D   0.46   0.60 
 
Table No:VII c. Robustness of High 
Temp(27 C);   
     
  Metformin HCl Voglibose 
S.NO AUC Assay in % AUC Assay in % 
1 13580524 100.9 121525 101.1 
2 13292485 98.6 123046 102.4 
3 13334865 99.2 119400 99.4 
Mean   99.57   100.97 
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S.D   1.19   1.50 
R.S.D   1.20   1.49 
 
TableNo:VII d.Robustness of Low 
Temp(23OC):   
     
  Metformin HCl Voglibose 
S.NO AUC Assay in % AUC Assay in % 
1 13180524 99.0 120025 100.6 
2 13092485 98.0 118546 99.0 
3 13124865 98.1 118400 98.7 
Mean   98.37   99.43 
S.D   0.55   1.02 
R.S.D   0.56   1.03 
 
 
 
 
 
 
 
Table No:VII e.  Robustness of Mobile phase Changes (Buffer:ACN 
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400:600): 
     
  Metformin HCl Voglibose 
S.NO AUC Assay in % AUC Assay in % 
1 13680524 102.2 122653 102.5 
2 13352485 99.9 121542 101.7 
3 13854865 103.2 122412 102.0 
Mean   101.77   102.07 
S.D   1.69   0.40 
R.S.D   1.66   0.40 
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Table No:VII f. Robustness of Mobile phase Changes (Buffer:ACN 
360:640): 
     
  Metformin HCl Voglibose 
S.NO AUC Assay in % AUC Assay in % 
1 13280524 99.7 121653 102 
2 13392485 100.2 117546 98.1 
3 13024865 97.3 119412 99.5 
Mean   99.07   99.87 
S.D   1.55   1.98 
R.S.D   1.56   1.98 
 
 
 
 
 
 
 
 
  
  
85 
 
 
Table No:VII g.  Robustness of High 
pH(6.7): 
     
  Metformin HCl Voglibose 
S.NO AUC Assay in % AUC Assay in % 
1 13411089 99.4 121055 101.5 
s2 13292485 98.6 123046 102.4 
3 13532506 100 122890 102.9 
Mean   99.33   102.27 
S.D   0.70   0.71 
R.S.D   0.71   0.69 
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Table No:VII h. Robustness of 
LowpH(6.3): 
     
  Metformin HCl Voglibose 
S.NO AUC Assay in % AUC 
Assay in 
% 
1 13370026 99.3 120601 100.3 
2 13418095 99.7 122999 102.4 
3 3434540 99.8 122562 102.0 
Mean   99.60   101.57 
S.D   0.26   1.12 
R.S.D   0.27   1.10 
 
Result: 
    The assay of Metformin HCl and Voglibose was found 97.0% to 103.0%. 
 
 
 
 
 
 
87 
 
CALCULATION: 
Amount of Metformin HCl present in mg: 
  =          A x Ws x 500 x P x Aw x1000 
      B x 500x Wt taken x 100 
Amount of Metformin HCl in mg: 
=     13370026 x 500 x  500 x 100 x 0.7620 X 1000 
            13460528 x 500 x 0.7625 x 100 
=    496.93mg 
Assay in %      =        497.93 x 100               
                                        500 
                       = 99.3% 
Amount of Voglibose present in mg: 
   A x Ws x 5x 5 x 500 x P x Aw x1000 
   B x 100x50x 500 x Wt taken x 100 
Assay of Voglibosein mg: 
 =   120601 x 60 x 5 x 5 x 500 x 99.62 x 0.7620X 1000      = 0.3012mg 
     120173 x 100 x 50 x 500 x 0.7625 x 100                                             
Assay in %     =        0.3002 x 100            = 100.3% 
                                         0.3 
Observation :  when flow rate was changed Rt had changed significantly, 
when mobile phase was changed there was change  in the Rt  had changed 
significantly, when the temperature and pH were changed there were no 
changes observed. So care must be taken while selecting the mobile phase and 
flow rate. 
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                   While changing all the above parameters the assay% was observed 
to be within limit 
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SUMMARY  
   A very few analytical methods appeared in the literature for the 
determination  of  Metformin HCl and Voglibose are generally based 
HPLC,UV, Spectrofluorimetry that has been reported for the quantification of  
Metformin HCl and Voglibose. 
In the present work, an attempt was made to provide a newer, simple, accurate 
and low cost  post column derivatization of spectrophotometric and there 
derivative method and one HPLC method for the effective quantitative 
determination of Metformin HCl and Voglibose as an active pharmaceutical 
ingredient as well as in pharmaceutical preparations without the interferences 
of other constituent in the formulations. 
For routine analytical purposes it is always of interest to establish methods 
capable of analysing a large number of samples in a short time period with 
good accuracy and precision. The main purpose of this study was to develop 
accurate, precise and economic methods for the determination of Metformin 
HCl and Voglibose. Spectrophotometric technique, and post column 
derivatization method were applied without using any prior chemical 
pretreatment in the presence of the strongly overlapping spectra can generate 
large amounts of data within a short period of analysis.  
An HPLC method is developed and validated for various parameters as per 
ICH guidelines. The system suitability parameters prove that the proposed 
method is equally suitable for estimation of Metformin HCl and Voglibose, the 
chromatogram for Metformin HCl and Voglibose were found to be satisfactory 
on Phenomenex –amino 100A  RP-18(2), 250X4.6mm, 5 m column, using 
mobile phase composition of Buffer:Acetonitrile [380:620(v/v)] with flow rate 
of 1.0 ml/min. Both the peaks were found to be symmetrical as found from 
symmetry factor of 1.01 for Metformin HCl and Voglibose.  
The resolution of the proposed method was found to be satisfactory, with peak 
showing complete base line separation. The retention time for Metformin HCl 
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about 5 min. and Voglibose was about 13 min. The proposed system of 
stationary phase and mobile phase was ideally suitable for the estimation as 
indicated by good number of theoretical plates 5689 per meter for Metformin 
HCL and Voglibose. 
The sensitivity of the method is good and also linearity which is observed 
good. 
The accuracy of method is determined by recovery with spiked concentration 
of pure drug at three levels for Metformin HCl and Voglibose. The recovery of 
drug is well within the acceptance limits of 97-103%. 
The robust method is as observed from insignificant variation in the results of 
analysis on changes in mobile phase composition ratio, pH, Flow rate, and 
Temperature and analysis being performed by different analysts and on different 
days respectively. In all the above cases the recovery is found to be within the 
limit. 
Result:   Chromatographic Condition 
Parameters Description 
Column C18:250X4.6mm, 5µ,amino SS Column 
Mobile Phase Buffer:ACN(380:620) 
Flow rate 1.0ml/min 
Flow rate fluorescence reagent 1.0ml/min 
Detection for Metformin HCl UV-254nm 
Detection for Voglibose Spectrofluorimeter 
Excitation wavelength 350nm 
Emission wavelength 430nm 
Temperature 25OC 
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Injection volume 20µl 
Run time 20min 
Diluent Purified water 
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CONCLUSION 
The present study was validated as per the ICH guidelines From the 
comparative study, it was inferred that the method is simple, specific, precise, 
linear, sensitive, and also system suitability. The results obtained on the 
validation parameter met the respective acceptance criteria. 
The method was found to have suitable application in routine laboratory 
analysis and with high degree of accuracy and precision From the 
comprehensive validation conducted, it was concluded that the method is stable 
and could be used throughout shelf life of the drug. 
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